Effect of zoledronic acid on osteoporosis for the chronic stroke patients- prospective multicenter intervention study - Effect of zoledronic acid on osteoporosis for the chronic stroke patients

Fujiwara Toshiyuki0 个研究点目标入组 0 人开始时间: 2019年9月3日最近更新: 2023年10月17日

适应症

试验速览

This study was ended without registration of subjects.

•1.Hemiparesis patients based on first onset stroke.
•2.Age more than 60 years.
•3.More than 90 days from onset of stroke.
•4.Patients who could come to outpatients clinic following to the study protocol.
•5.Witten informed consent.

•1)Patients receiving other therapies which affect bone metabolism (teriparatide, denosumab, bisphosphonate injection and zoledronic acid).
•2)Allergy against zoledronic acid or other bisphosphonate.
•3)Severe renal failure ( eGFR<35ml/min)
•4)Hypocalcemia (albumin-adjusted Ca <8.5mg/dl)
•5)Severe complications
•6)History of operation for lumber spine or femur fracture.
•7)Severe denegerative spondylosis or severe hip arthrosis
•8)Currently receiving invasive dental treatment such as tooth extraction, or shortly after tooth extraction
•9) History of osteonecrosis of jaw

发起方

Fujiwara Toshiyuki